NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Details
- Status
- Prescription
- First Approved
- 2021-01-15
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Approval History
What NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Treats
1 indicationsNOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypotension
Drugs Similar to NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE FDA Label Details
ProIndications & Usage
FDA Label (PDF)Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine bitartrate injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states.
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Patents & Exclusivity
Patents (15 active)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.